The effect of 0.1% topical ciclosporin a for 12-weeks on the ocular surface innate and adaptive immune response in dry eye disease: protocol for a randomized controlled clinical trial.
Ann MedSep 19, 2026 (epub)
Clinical ResearchOphthalmology
Soumen Sadhu, Isabelle Jalbert, Mengliang Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial protocol aims to evaluate the effects of 0.1% topical ciclosporin A combined with mineral oil eye drops versus mineral oil eye drops alone on the ocular surface immune response in 60 participants with moderate-to-severe dry eye disease over 12 weeks. The study will assess immune cell changes and tear cytokine levels.
Key findings
- Participants will be randomized 1:1 into two groups: CsA plus mineral oil or mineral oil alone.
- Corneal immune cells will be assessed using static in vivo confocal microscopy and functional-IVCM.
- Tear cytokine analyses will include IL-2, IL-4, IL-6, IL-12, IL-17, IL-23, and IFN-γ.
Why it matters
Understanding the impact of ciclosporin A on ocular surface immune responses could enhance treatment strategies for dry eye disease, potentially leading to improved patient outcomes through better-targeted therapies.